CRANBURY, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop […]
Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical StudyData Supports Continued […]
— Alkaline88® will join Core-Mark’s “Smart Stock®” program that caters to approximately 11,000 convenience stores nationwide.— The Company also announced […]